世界卫生组织定义的高卫生支出国家天然健康产品行业药物警戒监管要求(2020年):范围综述
该范围综述梳理了世界卫生组织2020年最高当前卫生支出30个国家/地区中天然健康产品(NHP)行业药物警戒监管要求。最终纳入12个国家/地区的公开监管文件,发现NHP定义与监管框架差异明显,多数辖区要求行业在获知严重不良反应后15天内报告,但外国报告、定期安全性更新报告、文献筛查及药物警戒负责人等要求不同;按食品类监管的NHP要求通常更少或没有。
要点
- 多数辖区要求NHP行业在获知严重不良反应后15天内报告。
- NHP定义与监管框架在辖区间及辖区内部存在差异。
- 按食品监管的NHP药物警戒要求通常少于按药品监管的NHP。
核心结论
- NHP行业药物警戒监管要求在国家/地区间及内部存在差异,主要聚焦于严重不良反应报告。
研究设计与样本
- 范围综述:识别WHO 2020年当前卫生支出最高的30个国家/地区,检索官方政府网站及选定二手资源中可公开获取的英文监管文件。
- 最终纳入12个国家/地区(澳大利亚、巴西、加拿大、中国、印度、日本、韩国、南非、瑞士、英国、美国及欧盟)的监管文件。
主要发现
- NHP定义在各辖区间存在差异。
- 监管框架在纳入NHP的单一药品体系与对不同NHP类别分别适用药品和食品基础立法的体系之间差异最明显。
- 多数纳入辖区要求NHP行业(产品申办者、上市许可持有人、注册/许可证持有人、制造商)在获知严重药物不良反应报告后15天内报告。
- 对外国药物不良反应报告、定期安全性更新报告、文献筛查及药物警戒合格人员的要求存在差异。
- 对按食品监管的NHP,行业药物警戒要求通常少于或没有要求,而按药品监管的NHP要求更多。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Pharmacovigilance is the science and practice of safety monitoring for medicines-related problems; it is also applicable to a broader scope of health products, including natural health products (NHPs). The NHPs industry is a key stakeholder in pharmacovigilance for NHPs, but academic review of regulatory requirements concerning pharmacovigilance for the NHPs industry is limited. OBJECTIVES: To map, describe and compare regulatory requirements for the NHPs industry regarding pharmacovigilance for NHPs in selected international jurisdictions. METHODS: The top 30 countries/regions from the World Health Organization's (WHO) list of nations with the highest Current Health Expenditure in 2020 were identified. For these countries/regions, publicly accessible regulatory instruments describing pharmacovigilance requirements for the NHPs industry, available in English on official governmental websites and selected secondary resources, were sought. RESULTS: Regulatory documents from 12 countries/regions (Australia, Brazil, Canada, China, India, Japan, Republic of Korea, South Africa, Switzerland, UK, USA and the EU) were included. Definitions of NHPs vary across jurisdictions, while regulatory frameworks most clearly diverge between single medicine-based systems that include NHPs, and those that apply separate medicine- and food-based primary legislation to different NHP categories. Most included jurisdictions require the NHPs industry (i.e., product sponsors, market authorisation holders, registration/license holders, manufacturers) to report serious adverse drug reactions (ADRs) within 15 days of becoming aware of such reports. However, requirements for submitting foreign ADR reports, periodic safety update reports, conducting literature screening, and employing a Qualified Person for Pharmacovigilance differ. In jurisdictions that apply separate medicine- and food-based primary legislation to different NHP categories, pharmacovigilance requirements for the industry correspondingly vary. There are usually fewer (or no) requirements for products regulated as food compared with those included under medicine-based regulations. CONCLUSIONS: Pharmacovigilance regulatory requirements for the NHPs industry vary between and within countries/regions, primarily focusing on reporting serious ADRs. To support effective benefit-risk assessment of NHPs and safeguard public health, future policy-oriented research should assess the impact of these regulatory differences on industry practice and for pharmacovigilance for NHPs, examine requirements in countries not included here, and explore pathways towards international regulatory harmonisation. Pharmacovigilance is the science and practice of safety monitoring for medicines-related problems; it is also applicable to a broader scope of health products, including natural health products (NHPs). The NHPs industry (such as manufacturers, sponsors, market authorisation holders, registration/license holders) is a key stakeholder in pharmacovigilance for NHPs. This review discusses pharmacovigilance regulatory requirements for the NHPs industry in 11 countries (Australia, Brazil, Canada, China, India, Japan, Republic of Korea, South Africa, Switzerland, UK, USA) and the European Union (EU). Pharmacovigilance regulatory requirements vary between and within countries/regions. In countries/regions with regulations for NHPs, there are some requirements for the NHPs industry to report to the regulatory authority serious adverse drug reactions (ADRs) associated with NHPs, or some specific types of NHPs. Typically, serious ADRs must be reported by the NHPs industry within 15 days of becoming aware of the event. Also, within some countries/regions, the NHPs industry has fewer (or no) ADR reporting requirements for NHPs regulated as food than for those regulated as medicines. To support effective benefit–risk assessment of NHPs and safeguard public health, future policy work should examine how differences in regulations affect the industry and safety monitoring of these products, review regulations in countries not covered in this study, and explore strategies towards aligning regulations internationally.
引用
- Lim XY, Ram S, Scahill S, et al. Pharmacovigilance Regulatory Requirements for the Natural Health Products (NHPs) Industry in World Health Organization-Defined High Health Expenditure Countries (2020): A Scoping Review. Drug Saf. 2026. PMID: 42050312. doi:10.1007/s40264-026-01674-6
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。